1. Home
  2. SPE vs FHTX Comparison

SPE vs FHTX Comparison

Compare SPE & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Special Opportunities Fund Inc

SPE

Special Opportunities Fund Inc

N/A

Current Price

$11.51

Market Cap

135.0M

Sector

Finance

ML Signal

N/A

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

N/A

Current Price

$1.79

Market Cap

111.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPE
FHTX
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.0M
111.1M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
SPE
FHTX
Price
$11.51
$1.79
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $4.17
AVG Volume (30 Days)
50.1K
★ 685.0K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 8.55%
N/A
EPS Growth
N/A
★ 25.32
EPS
N/A
★ 0.43
Revenue
N/A
★ $30,909,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$4.14
Revenue Growth
N/A
★ 36.75
52 Week Low
$11.67
$1.73
52 Week High
$15.56
$7.61

Technical Indicators

Market Signals
Indicator
SPE
FHTX
Relative Strength Index (RSI) 24.57 33.87
Support Level N/A N/A
Resistance Level $13.71 $2.28
Average True Range (ATR) 0.21 0.17
MACD -0.04 0.03
Stochastic Oscillator 0.58 7.27

Price Performance

Historical Comparison
SPE
FHTX

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.

Share on Social Networks: